Home
Site Search
Use small fonts Use medium fonts Use large fonts Email link to page

Resources

Canada’s Excessive Pricing Regulations Survive Another Constitutional Challenge

Published: 03/08/2017

By Steven Kennedy

The Patented Medicine Prices Review Board (the PMPRB) commenced a proceeding against Alexion Pharmaceuticals Inc. (Alexion) in respect of Alexion’s drug, SOLIRIS (eculizumab), which is used to treat rare and devastating blood and genetic conditions. The PMPRB claimed and successfully argued that Alexion was selling Soliris at an excessive price, under sections 82 and 85 of the Patent Act.

Read more about the PMPRB proceeding against Alexion Pharmaceuticals Inc.